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Abstract: The Pancreatic Cancer Collaborative Registry (PCCR) is a multi-institutional web-based system aimed to collect a variety of 
data on   pancreatic cancer patients and high-risk subjects in a standard and efficient way. The PCCR was initiated by a group of experts 
in medical oncology, gastroenterology, genetics, pathology, epidemiology, nutrition, and computer science with the goal of facilitating 
rapid and uniform collection of   critical information and biological samples to be used in developing diagnostic, prevention and treat-
ment strategies against pancreatic cancer. The PCCR is a multi-tier web application that utilizes Java/JSP technology and has Oracle 
10 g database as a back-end. The PCCR uses a “confederation model” that encourages participation of any interested center, irrespective 
of its size or location. The PCCR utilizes a standardized approach to data collection and reporting, and uses extensive validation proce-
dures to prevent entering erroneous data. The PCCR controlled vocabulary is harmonized with the NCI Thesaurus (NCIt) or Systematized 
Nomenclature of Medicine-Clinical Terms (SNOMED-CT). The PCCR questionnaire has accommodated standards accepted in cancer 
research and healthcare. Currently, seven cancer centers in the USA, as well as one center in Italy are participating in the PCCR. At pres-
ent, the PCCR database contains data on more than 2,700 subjects (PC patients and individuals at high risk of getting this disease). The 
PCCR has been certified by the NCI Center for Biomedical Informatics and Information Technology as a cancer Biomedical Informatics 
Grid (caBIG®) Bronze Compatible product. The PCCR provides a foundation for collaborative PC research. It has all the necessary pre-
requisites for subsequent evolution of the developed infrastructure from simply gathering PC-related data into a biomedical computing 
platform vital for successful PC studies, care and treatment. Studies utilizing data collected in the PCCR may engender new approaches 
to disease prognosis, risk factor assessment, and therapeutic interventions.
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Introduction
Pancreatic Cancer (PC) is the fourth leading cause of 
cancer death in both men and women.1,2 The anatomic 
location of the pancreas, deep in the abdomen, has 
hampered early detection. Despite progress in imag-
ing techniques, most cancers smaller than 1 cm remain 
undetected. Since symptoms occur late, patients with 
PC  usually  present  at  an  advanced  disease  stage. 
About 80% of patients have metastatic disease by 
the time of their first clinical visit. Despite intense 
research in this area, the prognosis of patients with 
PC has remained dismal. The etiology of the disease 
is obscure and the epidemiological data is, in part, 
controversial. Some suggested factors that seem to 
affect the risk of PC development include age, race, 
gender, genetics, and lifestyle habits (such as physi-
cal activity, smoking, drinking, and diet); however, 
inconsistent results hamper general understanding of 
their role in PC induction and/or promotion.3–11
Some PC cases exhibit a definite familial cluster-
ing and about 10% of cases are due to the hereditary 
factors.12–14 The role of hereditary factors and genetic 
predisposition to this disease are also poorly under-
stood and appear to be complex. The reported data 
are difficult to compare and risk factors are not yet 
well  defined.  The  registration  and  monitoring  of 
PC-prone families are very useful resources for the 
identification of susceptibility genes and the develop-
ment of early detection, surveillance and prevention 
strategies. The obviously higher incidence of PC in 
this high-risk population offers an avenue to prospec-
tively collect detailed clinical, biochemical, genetic, 
nutritional,  habitual,  molecular  biological  and 
  environmental information that can shed light on risk 
factors, prevention and therapy, as well as an elucida-
tion of early symptoms of this disease. A   comparison 
of the information gained from this group and from 
sporadic cases is of considerable clinical and epide-
miological importance.
In most cases PC development appears sporadic, 
with most well established risk factors having only 
a small effect. Resolving a multifactor and complex 
condition  requires  careful  ascertainment  and  com-
parison of large numbers of subjects. Since even the 
top centers see only a few hundred cases per year, 
adequately powered PC studies will require recruit-
ment of PC patients across the country and around the 
world. Furthermore, it will be necessary to   establish 
a  close  information  partnership  between  multiple 
centers with expertise in PC epidemiology, genetics, 
biology, pathology, early detection and patient care. 
This can be accomplished only by design and imple-
mentation  of  an  advanced  biomedical  computing 
platform thereby allowing the researchers to collect 
and process PC-related data in a unified and conve-
nient way. The development of a standardized man-
ner of data collection, together with a comprehensive 
plan for registering all PC cases and collecting data 
on individuals at high risk of developing PC, as well 
as on PC-free individuals for the case control studies, 
are fundamental needs for achieving a better knowl-
edge of this disease. Standardization of the data and 
terminology models is essential in order to develop 
methods and databases that will allow clinicians and 
researchers to make computerized validation, mine 
clinical and biological data, and define more reliable 
environmental and behavioral risk factors, which may 
contribute to the development of this disease.
To address all of these challenges, the Pancreatic 
Cancer  Collaborative  Registry  (PCCR)  was  initi-
ated in 2000 as a pilot project of the NCI Special-
ized  Programs  of  Research  Excellence  (SPORE) 
grant awarded to the UNMC Eppley Cancer Center. 
In 2001, representatives of several universities and 
the NCI agreed to participate in the development of 
the expanded PCCR infrastructure that would pro-
vide a standardized collection and sharing of clini-
cal and demographic information on PC patients and 
individuals at high risk of PC development, as well 
as information on biospecimens collected from these 
subjects.
The goal of this paper is to describe the   biomedical 
informatics aspects of the PCCR development, orga-
nizational  procedures  supporting  the  PCCR  activi-
ties,  and  to  present  overall  statistics  of  the  PCCR 
enrollment.
Methods
PCCr architecture
The  PCCR  team  elected  to  use  a  “confederation 
model”, as opposed to traditional registry or network 
models that assume control of an individual center’s 
data. “Confederation” assumes that each participat-
ing site (institution) retains all rights to the acquired 
data that can be used by other PCCR participants only 
after obtaining required permissions and by   providing Pancreatic cancer collaborative registry
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  corresponding  references  and  acknowledgements. 
It was also recognized that for this model to be suc-
cessful, it is essential to have a standardized approach 
to  data  collection  and  reporting.  A  confederation 
would also encourage participation of any interested 
center, regardless of its size or location.
The PCCR has been implemented using a three-
tier, Web-based architecture: i) a client that interacts 
with the user; ii) an application server that contains the 
business logic of the application; and iii) a resource 
manager that stores the data. The PCCR utilizes Java 
Servlet/JSP technology and has Oracle 10g database 
as a back-end.
Standardization of data
To create a potential for integration with other related 
data sources, the PCCR team defined and established 
the criteria for standardization of collection forms and 
identified research questions that had to be addressed. 
Questionnaires well recognized in the cancer research 
community (for example, the NCI Quick Food Scan 
Percent Fat Screener questionnaire15 and the NCCN/
FACT hepatobiliary/pancreas symptom index16) have 
been implemented into the PCCR. When creating the 
physical activity form, the American Cancer   Society’s 
(ACS) examples of moderate versus vigorous physical 
activity guidelines for cancer prevention were used.17
Consistent with the “confederation” concept, the 
PCCR team has agreed upon a Core Data Set of infor-
mation that all participating centers must provide and 
share with the PCCR community. The required (core) 
data elements include the most common questions 
used in clinical, epidemiological, nutritional, phar-
maceutical, and quality of life studies. The core data 
set also includes the following administrative data 
elements: date when the case was submitted, current 
status of the case, registering institution code, person 
completing the case, and subject identification code.
Optional data elements cover a variety of   questions 
that provide additional information for PC   researchers. 
It is the individual participating center’s decision to 
collect additional data and detailed information that 
make up the Complete Data Set.
The main areas covered by the PCCR question-
naires are presented in Table 1.
According to rules accepted by the PCCR team, 
a  subject  may  provide  information  on  personal, 
  demographic,  lifestyle,  physical  activity,  dietary 
habits,  family  history,  women’s  health,  genetics 
data, symptoms, quality of life, and medical history; 
whereas information on diagnostic studies, pathology/
staging, treatment, surgeries, biospecimens, and sur-
vival can be provided only by the clinical personnel.
All  terms  of  the  PCCR  controlled  vocabulary 
have an explicit numeration and are described by an 
unambiguous, non-redundant definition drawn from 
the NCI Thesaurus or SNOMED-CT. The data ele-
ments have been defined based on the NCICB   Cancer 
Data  Standards  Registry  and  Repository  (caDSR) 
  convention. When possible, the PCCR data elements 
were mapped to the caDSR.
PCCr web interface
The PCCR public website (see Fig. 1) can be acc-
essed  at  http://pccrproject.org.  The  PCCR  user 
interface is designed to eliminate ambiguity in the 
data collected and assist users with accuracy and ease 
of completion. The collection forms have predeter-
mined  selection  choices  whenever  possible. As  an 
example, Figure 2 presents a fragment of the dietary 
collection  form. The  validation  components  in  the 
PCCR interface prevent the users from entering erro-
neous information into the system.
Integration with the caTissue
To ensure that the biospecimen data are collected in 
a standard and efficient way, the caTissue Suite18 has 
been adopted and integrated into the framework to 
manage biospecimen data. The PCCR’s case number 
Table 1. Core data elements.
category Data elements
Demographic race, ethnicity, gender, Year of birth, 
State/Country of residence, education
Lifestyle Smoking habits and Alcohol consumption
Family history Data on relatives with history of cancer: 
Year of birth, Cancer type, Smoking 
status, Survival
Medical data Weight, height, BMI, Cancer type, Year 
of diagnosis, Stage, Major diseases
Diagnostic Dates and types of diagnostic procedures
Treatment Type of treatment, Agent, Schedule, 
Dosage, response
Biospecimens Types of collected specimens, Amount, 
Date, Pre/post-operative, Storage
Outcome Date of last contact, SurvivalSherman et al
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Figure 1. The PCCr website.
is used to link the biospecimen data with data col-
lected in a registry.
PCCr security
The patients’ personal information collected in the 
PCCR  is  protected  using  recommendations  of  the 
Healthcare  Information  and  Management  Systems 
Society (HIMSS) Privacy and Security Toolkit and 
the  electronic  information  security  standards  man-
dated  by  the  Federal  Health  Insurance  Portability 
and Accountability Act (HIPAA). According to the 
HIMSS, a complete security solution that maximizes 
the benefits of networked data communications must 
contain the following elements: User Authentication, 
Access Control, Encryption, Physical Protection, and 
Management.19 User authentication, access control, 
and data encryption issues have been addressed   during 
the application development, while physical protec-
tion and network management have been provided by 
the UNMC Information Technology Services.
The PCCR system is accessible to registered users 
at participating sites only. To ensure that users have the 
authority to proceed with data entry, authorized users 
are issued their own unique electronic   signature—a 
combination of a user name and a password.
Each user has an appropriate level of access to 
data. There are six user roles, each of which has a 
particular type of authority (see Table 2).
All subjects’ protected health information (PHI) 
collected  in  the  PCCR  is  encrypted  when  entered 
into the database. It can only be decrypted if the user 
has the corresponding level of access. To decrypt the 
PHI, the private key is sent to the database function 
from the application. The private key is only sent if the Pancreatic cancer collaborative registry
Cancer Informatics 2011:10  87
protocol templates and privacy assurances in proce-
dures  of  informed  consent  were  formulated  detail-
ing  the  use  of Web-based  tools. The  template  also 
includes: a) methods and procedures applied to human 
subjects; b) data storage and confidentiality; c) poten-
tial risk assessment for human subjects; d) risk clas-
sification; e) protection against the potential risks for 
human  subjects;  f)  potential  benefit  assessment  for 
human subjects; g) potential benefits to society; and h) 
alternatives to participation. In addition to the elements 
of informed consent required by 45CFR46.116(a), a 
model consent form includes the following HIPAA-
mandated information: i) a specific description of the 
information to be used or disclosed; ii) the person or 
entity to whom disclosure will be made; iii) the purpose 
of the use or disclosure; iv) an expiration date or event 
Figure 2. example of the PCCr user interface.
user is authorized to access this data. The fact that the 
database and application servers are located in differ-
ent network zones minimizes the risk of unauthorized 
access to PHI, even if the database is compromised.
The system utilizes secure web server communi-
cation and supports Secure Socket Layer (SSL) (an 
Internet  encryption  method  that  provides  two-way 
encryption along the entire route that data travels to 
and from a user’s computer) and HTTPS authentica-
tion (the communications standard used to transfer 
pages on the Web).
IrB and subject recruitment
To  utilize  the  PCCR,  each  participating  center  is 
required  to  obtain  approval  from  its  Institutional 
Review Board (IRB) or Ethics Committee. Standard Sherman et al
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for use of the information; v) an explanation of how 
authorization may be revoked; and vi) any restrictions 
placed on the   subject’s access to the information with 
access granted upon completion of the research. All 
participating investigators are able to use these stan-
dardized statements to assist with IRB applications.
All investigators and research staff are required to 
complete the computer-based training course on the 
Protection of Human Research Subjects, approved by 
the Office for Human Research Protections of the US 
Department of Health and Services. All information 
gathered in the PCCR must be in accordance with 
IRB approval and monitored with an annual review 
by each center’s IRB. A copy of the IRB approval 
letter for each site has been submitted to the PCCR 
Coordinator at UNMC.
In order to enter data into the PCCR, a consent 
form for each subject must be obtained. Under the 
informed consent process, study participants are asked 
to voluntarily participate in the PCCR. The potential 
participants, a PC patient or unaffected subject, are 
asked about their willingness to share the informa-
tion they provided in the PCCR with research col-
laborators. The subjects are informed in the consent 
that: i) the information they provide is collected for 
research purposes only; ii) their PHI will be encrypted 
prior to the submission of the data into the PCCR; 
iii)  they  may  revoke  the  authorization  to  use  and 
share their PHI at any time by contacting the princi-
pal investigator in writing; and iv) if they revoke this 
  authorization, the use or sharing of future PHI will 
be stopped, and that the PHI, which has already been 
collected, may still be used. The instructions for com-
pleting the Web-based or the paper questionnaires are 
given to the participant in person while they attend 
the clinic or mailed to their home address. Available 
staff gives a verbal explanation of the forms or assis-
tance with the Website. The subject may also contact 
the PCCR Coordinator for assistance.
Descriptions  of  human  subjects’  rights  regard-
ing  privacy  and  consent  issues  in  epidemiological 
research were addressed according to the HIPAA reg-
ulations 45CFR46.102(d) to ensure that patient confi-
dentiality is appropriately protected and that research 
can  be  accomplished  with  minimum  disclosure  of 
the patient’s PHI. For the purposes of data mining, 
the subject’s PHI is de-identified by deleting specific 
identifiers; such as names, all geographic subdivisions 
smaller than a state or a zip code, all elements of dates 
(except year) for dates directly related to an individ-
ual (birth date, etc.), telephone numbers, fax numbers, 
electronic mail addresses,  social security numbers, 
medical record numbers, and any other unique iden-
tifying number, characteristic, or code. Researchers 
with an IRB approval and Data Use Agreement (see 
below) can utilize and disclose PHI that contains a 
limited data set without HIPAA authorization or a 
waiver of consent granted by the IRB. The limited 
data set is PHI from which the 16 direct identifiers 
listed at 45CFR164.514(e)(2) of the HIPAA Privacy 
Rule have been removed.
Importantly, a multi-center Certificate of Confiden-
tiality (COC) from the National Cancer Institute was 
obtained on behalf of the Secretary of the Department 
of Health and Human Services to prevent a court of 
law from being able to subpoena the PCCR records. 
The COC applies to all institutions participating in 
the registry. The certificate protects the researchers 
from revealing the personal identity of a participant in 
this registry in any federal, state, local, civil, admin-
istrative, legislative, or other proceedings. The Cer-
tificate of Confidentiality is intended to protect only 
the confidentiality of the medical history and genetic 
test result data collected as part of this research study. 
It  does  not  protect  information  from  this  registry 
required for audit or program evaluation by the US 
Department of Health and Human Services, requested 
by the Food and Drug Administration, placed in a 
Table 2. PCCr user roles and their authority.
Role Authority
Subject/patient Can enter/update personal,  
demographic, lifestyle, symptoms,  
QOL, family and medical history data
Lab technician Can enter/update biospecimen data  
only
Clinician All of the above + enter medical data,   
retrieve and edit existing cases of  
his/her patients
Coordinator All of the above for the assigned 
clinicians
Center manager All of the above + retrieve and edit  
cases of the patients of the  
center/institution
System 
coordinator
All of the above + retrieve and edit  
all cases, activate/suspend users, 
assign the user authoritiesPancreatic cancer collaborative registry
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health care   provider’s medical records, or disclosed 
voluntarily by the subject or someone with whom the 
subject has shared this information.
Data use agreements
An Advisory and Prioritization Committee (Steering 
Committee) has been formed to oversee the develop-
ment of studies and projects that utilize information 
collected in the PCCR. The committee consists of 
an appointed member from each participating insti-
tution, as well as four external advisors, including a 
patient advocate, and the PCCR Coordinator. A major 
responsibility of this committee is to review and pri-
oritize proposed projects that utilize the registry and 
its resources.
Quality control
Quality and completeness of the collected data are 
ensured by multi-layer control (clinician, center man-
ager, system coordinator). Authorized users are pro-
vided with ad-hoc audit reports that highlight missing, 
incomplete,  or  potentially  erroneous  records.  The 
comprehensive training materials, defining a set of 
procedures and lines of responsibility, were distrib-
uted to the centers. To ensure consistency and reliabil-
ity of data collection across the participating centers, 
the PCCR system coordinator continuously provides 
educational  training  sessions  and  audits  submitted 
data, whereas individual center managers review the 
data submitted from their respective centers.
Results and Discussions
The PCCR is implemented as a bank of information 
with the ability to reference the institution and inves-
tigator where additional files/samples are located. The 
PCCR maintains an audit trail of all data entries to 
protect the authenticity, integrity and confidentiality 
of all data entries. The collaborators and representa-
tives from the centers utilizing the PCCR system have 
developed organizational and operational procedures, 
standardized IRB applications and common consent 
forms, as well as bylaws for stockholders participat-
ing in multi-center collaborations.
Until recently, the PCCR was the only cancer reg-
istry that has been certified by the NCI Center for 
Biomedical Informatics and Information Technology 
as a caBIG® Bronze Compatible product. In January 
2011, a similar system developed and   implemented at 
the UNMC, the Breast Cancer Collaborative Registry 
(BCCR, http://bccr.unmc.edu/), has also been certi-
fied as a caBIG® Bronze compatible product. Data 
collected in the PCCR are being used as a platform 
for several research projects, which should lead to a 
better understanding and treatment of PC.   Participants 
have being recruited through the PCCR website as 
well as advertising at professional conferences and 
  meetings. At present, seven cancer centers in the USA 
  (University of Nebraska Medical Center, Creighton 
University, North Shore University Health System, 
University of Pittsburgh, University of Alabama at 
Birmingham, University of Michigan Medical Center, 
and the Memorial Sloan Kettering Cancer Center), as 
well as one center in Italy (University of Genoa) are 
participating in the PCCR.   Currently, the PCCR data-
base contains data on more than 2,700 subjects (PC 
patients and high-risk   individuals). The statistics of 
the current enrollment (as of 1/5/2011) are presented 
in Table 3.
The PCCR’s success is based on the collabora-
tive  efforts  of  multiple  institutions  with  expertise 
in  medical  oncology,  gastroenterology,  genetics, 
pathology, pancreatic cancer epidemiology, nutrition, 
and  computer  science.  One  of  the  PCCR’s  advan-
tages is that all clinical and epidemiological informa-
tion is collected while a patient is still in clinic, which 
is imperative for the aggressive cancers such as PC. 
The PCCR offers a number of benefits to its users, 
including: i)   standardized data elements, vocabulary 
and forms for data collection; ii) collecting data by 
effective, secure, and easy to use web-based system; 
iii)   computerized audit and control of data   quality; 
iv)  access  to  the  bigger  data  set  for  data  analysis 
(separate  agreement  with  collaborating  centers  is 
required); and v) ability to collaborate with other cen-
ters participating in the PCCR activities.
The PCCR has all the necessary prerequisites for 
subsequent evolvement of the developed infrastruc-
ture from simply gathering PC-related data into a bio-
medical computing platform vital for successful PC 
studies, care and treatment.
In  the  future  developments,  the  caBIG®  tools 
will  be  utilized  to  develop  application  program-
ming  interfaces  (APIs)  to  virtually  integrate  data 
collected  in  the  PCCR  with  data  from  “external” 
registries,  such  as  Surveillance  Epidemiology  and 
End  Results  (SEER)  and  Behavioral  Risk  Factor Sherman et al
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  Surveillance   System (BRFSS). It will allow research-
ers to: i) assess cancer risk factors; ii) study behavioral 
changes among cancer survivors; iii) assess outcomes 
among racially and ethnically diverse communities; 
iv)   perform comparative analyses of effectiveness of 
different types of cancer treatment; v) develop pre-
clinical diagnostic and prognostic methods for early 
detection of cancer; and vi) develop predictive math-
ematical models for treatment outcomes.
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